ReviewCancer cell international2026
Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correction: Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy.Cancer cell international · 2026Article
- A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells play a central role in innate immune surveillance and represent a promising platform for next-generation cancer immunotherapy. Recent advances in chimeric antigen receptor (CAR) engineering have accelerated the development of CAR-NK cell therapies as potentially safer and more accessible alternatives to CAR-T cell therapy. Compared with CAR-T cells, CAR-NK therapies demonstrate lower risks of cytokine release syndrome and graft-versus-host disease while offering the potential for allogeneic "off-the-shelf" applications. Preclinical and early-phase clinical studies have shown encouraging antitumor activity of CAR-NK cells in both hematological malignancies and solid tumors. However, several translational challenges remain, including limited in vivo persistence, insufficient tumor trafficking, immunosuppressive tumor immune microenvironments, manufacturing variability, and restricted long-term clinical data. To overcome these barriers, emerging strategies such as CRISPR-based gene editing, cytokine-armored CAR constructs, multiplex engineering, checkpoint blockade combinations, and oncolytic virus-based approaches are being actively investigated. This review provides an updated overview of CAR-NK cell biology, engineering strategies, current clinical progress, major translational challenges, and future therapeutic opportunities. In addition, we discuss evolving combinatorial and next-generation engineering approaches that may improve persistence, safety, and therapeutic efficacy, ultimately facilitating the broader clinical translation of CAR-NK immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.